Skip to content

Released May 9, 2013, after the close

10-Q filed May 9, 2013, 39 days after period end · 0001193125-13-211191

Q1 2013 · 10-Q
Revenue$2.75M±0.0% vs Q1 2012+91.5% vs Q4 2012
Net Income-$16.49MN/M vs Q1 2012N/M vs Q4 2012
EPS Diluted-$0.11N/M vs Q1 2012no prior Q4 2012 on file
Gross Profit$2,357,000±0.0%
Operating Income-$6,611,000—
Operating Cash Flow-$5,331,000N/M
Margins · derived
Gross margin85.7%±0.0 pt vs Q1 2012
Operating margin-240.4%
Net margin-599.7%−216.6 pt vs Q1 2012

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2013Q1 2012Q1 2011
Revenue$2.75M$2.75M—
Net Income-$16.49M-$10.54M-$3.84M
EPS Diluted-$0.11-$0.52-$0.19

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR